"目录号: HY-13690
Mitotane(2,4′-DDD)是DDD的同分异构体和DDT的衍生物，有抗癌活性，可作用于肾上腺皮质癌。
相关产品
SBE-β-CD-MPTP hydrochloride-Cyclosporin A-Etomoxir-Auranofin-GKT137831-Ceruletide-Acetylcysteine-JC-1-BPTES-Brassinolide-FCCP-IPTG-MTT-RSL3 1S,3R--
生物活性
Description
Mitotane(2,4′-DDD), an isomer of DDD and derivative of DDT, is an antineoplastic medication used in the treatment of adrenocortical carcinoma.IC50 value: Target: Mitotane alters steroid peripheral metabolism, directly suppresses the adrenal cortex and alters cortisone metabolism leading to hypocortisolism. Side effects as reported by Schteinberg et al. include anorexia and nausea (88%), diarrhea (38%), vomiting (23%), decreased memory and ability to concentrate (50%), rash (23%), gynecomastia (50%), arthralgia (19%), and leukopenia (7%).
Clinical Trial
University of Turin, Italy
Adrenocortical Carcinoma
April 2008
Phase 3
University Health Network, Toronto
Prostate Cancer
September 2013
Phase 1
National Cancer Institute (NCI)
Recurrent Adrenocortical Carcinoma-Stage III Adrenocortical Carcinoma-Stage IV Adrenocortical Carcinoma
December 2008
Phase 2
National Cancer Institute (NCI)-National Institutes of Health Clinical Center (CC)
Adrenal Cortical Carcinoma
August 1993
Phase 2
Collaborative Group for Adrenocortical Carcinoma Treatment-German Federal Ministry of Education and Research-National Cancer Institute (NCI)
Carcinoma, Adrenal Cortical
June 2004
Phase 3
Children's Oncology Group-National Cancer Institute (NCI)
Stage I Adrenocortical Carcinoma-Stage II Adrenocortical Carcinoma-Stage III Adrenocortical Carcinoma-Stage IV Adrenocortical Carcinoma
September 2006
Phase 3
View MoreCollapse
References
